The immune-related adverse events associated with treatment with immune checkpoint
inhibitors result in significant morbidity for patients as well as considerable cost to the health …

Importance Immune checkpoint inhibitors (ICIs) are now a mainstay of cancer treatment.
Although rare, fulminant and fatal toxic effects may complicate these otherwise …

The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to
provide guidance on the management of immune-related adverse events resulting from …

Background Rheumatic and musculoskeletal immune-related adverse events (irAEs) are
observed in about 10% of patients with cancer receiving checkpoint inhibitors (CPIs). Given …

Paraneoplastic neurological syndromes (PNSs) comprise a group of disorders that can
affect any part of the nervous system in patients with cancer and frequently result from …

Expanding use of immune‐checkpoint inhibitors (ICIs) underscores the importance of
accurate diagnosis and timely management of neurological immune‐related adverse events …

Importance Encephalitis is a severe immune-related adverse event secondary to treatment
with immune checkpoint inhibitors (ICIs). The spectrum of ICI-induced encephalitis (ICI-iE) …

Patients with advanced malignancies treated with immune checkpoint inhibitors are at
increased risk for developing immune-related neurological complications. It is a …

Neuromuscular adverse events following cancer treatment with anti-programmed cell death
protein 1 (PD-1) monoclonal antibodies are relatively rare, yet potentially fatal. We …

Simple Summary The breakthrough of immunotherapy in melanoma has generated a
glimmer of hope for lethal triple negative breast cancer (TNBC). This review summarizes the …